AVITA Medical, Inc (RCEL)

Etorro trading 970x250
AVITA Medical, Inc (RCEL) Logo

About AVITA Medical, Inc

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company’s patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient’s own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California. Address: 28159 Avenue Stanford, Valencia, CA, United States, 91355

AVITA Medical, Inc News and around…

Latest news about AVITA Medical, Inc (RCEL) common stock and company :

Recap: AVITA Medical Q1 Earnings
08 Nov, 2021 FinancialContent

AVITA Medical (NASDAQ:RCEL) reported its Q1 earnings results on Monday, November 8, 2021 at 04:00 PM. Here's what investors need ...

AVITA Medical Reports First Fiscal Quarter 2022 Financial Results
08 Nov, 2021 Yahoo! Finance

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first fiscal quarter ended September 30, 2021. First Quarter Fiscal Year 2022 Highlights Total revenue increased 39% to $7.0 million compared to $5

Earnings Scheduled For November 8, 2021
08 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 ...

AVITA Medical, Inc. (RCEL) Soars 8%: Is Further Upside Left in the Stock?
05 Nov, 2021 Yahoo! Finance

AVITA Medical, Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AVITA Medical Announces Expanded Medicare Reimbursement to Outpatient Hospital and Ambulatory Surgical Centers
03 Nov, 2021 Yahoo! Finance

Effective January 1, 2022, a new code describes the RECELL® SystemVALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the Centers for Medicare & Medicaid Services (CMS) has approved AVITA Medical’s application for a Transitional Pass-

Regional Burn Conferences Feature 12 RECELL® System Data Presentations by Prominent Burn Surgeons
28 Oct, 2021 Yahoo! Finance

Data underscores broad clinical utility and health economic benefits of the RECELL® SystemVALENCIA, Calif. and MELBOURNE, Australia, Oct. 28, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that 12 RECELL® System data presentations will be shared at the upcoming Southern and Northeast R

AVITA Medical to Announce Fiscal First Quarter 2022 Financial Results
25 Oct, 2021 Yahoo! Finance

VALENCIA, Calif. and MELBOURNE, Australia, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its fiscal first quarter 2022 financial results after the market closes on Monday, November 8, 2021. In conjunction with such release, the Company plans to host a conf

VTWG's Holdings Imply 23% Gain Potential
21 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $270.75 per unit.

Notable Monday Option Activity: RCEL, DXCM, ALLK
20 Sep, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AVITA Medical Inc (RCEL), where a total volume of 996 contracts has been traded thus far today, a contract volume which is representative of approximately 99,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 94.5% of RCEL's average daily trading volume over the past month, of 105,350 shares..

How The Pieces Add Up: LABU Targets $101
16 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $101.46 per unit.

AVITA Medical to Present at the 2021 Cantor Virtual Global Healthcare Conference
13 Sep, 2021 FinancialContent
AVITA Medical to Participate at the Lake Street 2021 BIG5 Conference
31 Aug, 2021 FinancialContent
AVITA Medical Reports Fourth Quarter and Fiscal Year 2021 Financial Results
26 Aug, 2021 FinancialContent
Earnings Scheduled For August 26, 2021
26 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Gambling.com Gr (NASDAQ:GAMB) is likely to report quarterly earnings at $0.07 ...

Earnings Scheduled For August 25, 2021
25 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Jiayin Gr (NASDAQ:JFIN) is projected to report quarterly earnings at $0.21 per ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
17 Aug, 2021 FinancialContent

Tuesday morning, 282 companies set new 52-week lows. Key Facts: Alibaba Group Holding (NYSE:BABA) was the ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

FDA Approves AVITA Medical Vitiligo Trial With Fewer Participants
16 Aug, 2021 FinancialContent

TheFDA has approvedAVITA Medical Inc's(NASDAQ: RCEL) request to amend its pivotal trial evaluating RECELL ...

FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical’s Pivotal Study of the RECELL® System for Vitiligo Treatment
16 Aug, 2021 FinancialContent
AVITA Medical to Announce Fiscal Fourth Quarter 2021 Financial Results
12 Aug, 2021 FinancialContent
How The Pieces Add Up: XBI Headed For $216
05 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $216.21 per unit.

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
30 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

AVITA Medical Announces Inclusion in the Russell 3000 Index
29 Jun, 2021 FinancialContent
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
16 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results
15 Jun, 2021 FinancialContent
U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients
10 Jun, 2021 FinancialContent

Expanded indication for use includes RECELL System for treatment of full-thickness acute burn wounds of all sizes in pediatric and adult patients

AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors
01 Jun, 2021 FinancialContent
Investors Snatch RCEL 17.9% Cheaper Than Its Secondary Stock Offering
01 Jun, 2021 FinancialContent

Looking back to 96 days ago, AVITA Medical Inc (RCEL) priced a 2,795,000 share secondary stock offering at $21.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

How The Pieces Add Up: JKK Targets $0
20 May, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Morningstar Small-Cap Growth ETF (JKK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $0.00 per unit.

AVITA Medical, Inc (RCEL) is a NASDAQ Common Stock listed in , ,

970x250